Bottom line
FHLC vs IXJ: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and IXJ (iShares Global Healthcare ETF) share a meaningful slice of their top holdings — about 76% by weight.
But FHLC is far broader, holding 337 positions to 124 for IXJ, so beyond the top names it adds exposure IXJ doesn't have.
FHLC is cheaper at 0.084% vs 0.38% — a difference of $30 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +6.4% for IXJ (reporting dates differ).
Updated Nov 19, 2026
FHLC vs IXJ side by side
| FHLC | IXJ | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Fidelity | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 0.38% |
| Annual cost per $10k | $8.4 | $38 |
| 10-yr cost on $10k (prospectus) | $108 | $480 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +2.6% | +14.9% |
| 5-yr return (annualized) | +7.2% | +6.4% |
| 10-yr return (annualized) | +8.8% | +8.2% |
| Best quarter | +16.4% | +13.6% |
| Worst quarter | −13.1% | −11.8% |
| Net assets (fund) | $3.3B | $3.8B |
| Number of holdings | 337 | 124 |
| Portfolio turnover | 3% | 2% |
| Returns as of | Nov 30, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | IXJ | Difference |
|---|---|---|---|
| 2024 | +2.6% | +0.6% | +2.0% |
| 2023 | +2.5% | +3.5% | −1.0% |
| 2022 | −5.5% | −4.7% | −0.8% |
| 2021 | +20.4% | +19.5% | +0.9% |
| 2020 | +18.1% | +12.5% | +5.6% |
| 2019 | +21.9% | +23.4% | −1.4% |
| 2018 | +5.5% | +2.9% | +2.7% |
| 2017 | +23.3% | +20.3% | +3.0% |
| 2016 | −3.3% | −6.2% | +2.9% |
| 2015 | +7.0% | +5.9% | +1.1% |
Source: Fund prospectus bar charts
Holdings overlap
18 of FHLC's top 25 holdings also appear in IXJ's top 25.
| Holding | FHLC | IXJ |
|---|---|---|
| Eli Lilly & Co | 13.35% | 10.93% |
| Johnson & Johnson | 8.93% | 7.04% |
| AbbVie Inc | 6.42% | 5.12% |
| UnitedHealth Group Inc | 5.44% | 4.40% |
| Merck & Co Inc | 4.66% | 4.12% |
| Thermo Fisher Scientific Inc | 3.09% | 2.42% |
| Amgen Inc | 3.00% | 2.54% |
| Abbott Laboratories | 2.66% | 2.05% |
| Gilead Sciences Inc | 2.34% | 2.04% |
| Pfizer Inc | 2.06% | 1.78% |
| Bristol-Myers Squibb Co | 1.93% | 1.53% |
| CVS Health Corp | 1.92% | 1.71% |
| Intuitive Surgical Inc | 1.82% | 1.83% |
| Danaher Corp | 1.80% | 1.56% |
| Vertex Pharmaceuticals Inc | 1.76% | 1.64% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
FAQ
What is the difference between FHLC and IXJ?
Which is cheaper, FHLC or IXJ?
Should I own both FHLC and IXJ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.